▶ 調査レポート

希少皮膚疾患治療の世界市場2021年ー2031年:主要疾患別(全身性硬化症[強皮症]、表皮水疱症[EB]、尋常性天疱瘡、皮膚エリテマトーデス)、治療法別、流通チャネル別

• 英文タイトル:Rare Dermatological Disease Treatment Market (Major Indication: Systemic Sclerosis [Scleroderma], Epidermolysis Bullosa [EB], Pemphigus Vulgaris, and Cutaneous Lupus Erythematosus; Treatment: Corticosteroids, Immunosuppressants, Anti-inflammatory Agents, Antibiotics, Analgesics, and Others; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Rare Dermatological Disease Treatment Market (Major Indication: Systemic Sclerosis [Scleroderma], Epidermolysis Bullosa [EB], Pemphigus Vulgaris, and Cutaneous Lupus Erythematosus; Treatment: Corticosteroids, Immunosuppressants, Anti-inflammatory Agents, Antibiotics, Analgesics, and Others; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031「希少皮膚疾患治療の世界市場2021年ー2031年:主要疾患別(全身性硬化症[強皮症]、表皮水疱症[EB]、尋常性天疱瘡、皮膚エリテマトーデス)、治療法別、流通チャネル別」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2111A045
• 出版社/出版日:Transparency Market Research / 2021年8月18日
• レポート形態:英文、PDF、206ページ
• 納品方法:Eメール
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥782,325 (USD5,795)▷ お問い合わせ
  Site Licence¥1,187,325 (USD8,795)▷ お問い合わせ
  Enterprisewide¥1,592,325 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Transparency Market Research社の本調査資料では、希少皮膚疾患治療の世界市場を広く調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、主要疾患別(全身性硬化症[強皮症]、表皮水疱症[EB]、尋常性天疱瘡、皮膚エリテマトーデス)分析、治療法別分析、流通チャネル別分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)分析、競争状況などの項目を掲載しています。
・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場概要
・キーインサイト
・希少皮膚疾患治療の世界市場規模:主要疾患別(全身性硬化症[強皮症]、表皮水疱症[EB]、尋常性天疱瘡、皮膚エリテマトーデス)
・希少皮膚疾患治療の世界市場規模:治療法別
・希少皮膚疾患治療の世界市場規模:流通チャネル別
・希少皮膚疾患治療の世界市場規模:地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)
・競争状況

Rare Dermatological Disease Treatment Market – Scope of Report

TMR’s report on the global rare dermatological disease treatment market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators of the market during the forecast period from 2021 to 2031. The report provides revenue of the global rare dermatological disease treatment market for the period of 2017–2031, considering 2020 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global rare dermatological disease treatment market during the forecast period.

The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global rare dermatological disease treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global rare dermatological disease treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global rare dermatological disease treatment market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global rare dermatological disease treatment market.

The report delves into the competitive landscape of the global rare dermatological disease treatment market. Key players operating in the global rare dermatological disease treatment market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global rare dermatological disease treatment market that have been profiled in this report.

Key Questions Answered in Rare Dermatological Disease Treatment Market Report

What is the scope of growth of companies present in the global rare dermatological disease treatment market?
What will be the Y-o-Y growth of the global rare dermatological disease treatment market between 2021 and 2031?
What is the influence of changing trends in technologies on the global rare dermatological disease treatment market?
Will North America continue to be the most profitable market for rare dermatological disease treatment providers?
Which factors are anticipated to hamper the global rare dermatological disease treatment market during the forecast period?
Which are the leading companies in the global rare dermatological disease treatment market?

Research Methodology

A unique research methodology has been utilized by TMR to conduct a comprehensive research on the growth of the global rare dermatological disease treatment market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary methods referred to by analysts during the production of the global rare dermatological disease treatment market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the rare dermatological disease treatment market as primary methods.

These primary and secondary methods have provided exclusive information during interviews, which serves as a validation from the rare dermatological disease treatment market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global rare dermatological disease treatment market with accuracy. The study also uses the top-down approach to assess the revenues for each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global rare dermatological disease treatment market more reliably and accurately.

レポート目次

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Rare Dermatological Disease Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Rare Dermatological Disease Treatment Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Pipeline Analysis
5.2. Novel Therapies for Rare Dermatological Disease
5.3. Key Industry Events (Mergers, Acquisitions, Partnerships, Collaborations, etc.)
5.4. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
6. Global Rare Dermatological Disease Treatment Market Analysis and Forecast, by Major Indication
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Rare Dermatological Disease Treatment Market Value Forecast, by Major Indication, 2017–2031
6.3.1. Systemic Sclerosis (Scleroderma)
6.3.2. Epidermolysis Bullosa (EB)
6.3.3. Pemphigus Vulgaris
6.3.4. Cutaneous Lupus Erythematosus
6.4. Global Rare Dermatological Disease Treatment Market Attractiveness, by Major Indication
7. Global Rare Dermatological Disease Treatment Market Analysis and Forecast, by Treatment
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Rare Dermatological Disease Treatment Market Value Forecast, by Treatment, 2017–2031
7.3.1. Corticosteroids
7.3.2. Immunosuppressants
7.3.3. Anti-inflammatory Agents
7.3.4. Antibiotics
7.3.5. Analgesics
7.3.6. Others
7.4. Global Rare Dermatological Disease Treatment Market Attractiveness, by Treatment
8. Global Rare Dermatological Disease Treatment Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Rare Dermatological Disease Treatment Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Global Rare Dermatological Disease Treatment Market Attractiveness, by Distribution Channel
9. Global Rare Dermatological Disease Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Rare Dermatological Disease Treatment Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Rare Dermatological Disease Treatment Market Attractiveness, by Country/Region
10. North America Rare Dermatological Disease Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. North America Rare Dermatological Disease Treatment Market Value Forecast, by Major Indication, 2017–2031
10.2.1. Systemic Sclerosis (Scleroderma)
10.2.2. Epidermolysis Bullosa (EB)
10.2.3. Pemphigus Vulgaris
10.2.4. Cutaneous Lupus Erythematosus
10.3. Market Value Forecast, by Treatment, 2017–2031
10.3.1. Corticosteroids
10.3.2. Immunosuppressants
10.3.3. Anti-inflammatory Agents
10.3.4. Antibiotics
10.3.5. Analgesics
10.3.6. Others
10.4. North America Rare Dermatological Disease Treatment Market Value Forecast, by Distribution Channel, 2017–2031
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. North America Rare Dermatological Disease Treatment Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. North America Rare Dermatological Disease Treatment Market Attractiveness Analysis
10.6.1. By Major Indication
10.6.2. By Treatment
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Rare Dermatological Disease Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Europe Rare Dermatological Disease Treatment Market Value Forecast, by Major Indication, 2017–2031
11.2.1. Systemic Sclerosis (Scleroderma)
11.2.2. Epidermolysis Bullosa (EB)
11.2.3. Pemphigus Vulgaris
11.2.4. Cutaneous Lupus Erythematosus
11.3. Europe Rare Dermatological Disease Treatment Market Value Forecast, by Treatment, 2017–2031
11.3.1. Corticosteroids
11.3.2. Immunosuppressants
11.3.3. Anti-inflammatory Agents
11.3.4. Antibiotics
11.3.5. Analgesics
11.3.6. Others
11.4. Europe Rare Dermatological Disease Treatment Market Value Forecast, by Distribution Channel, 2017–2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Europe Rare Dermatological Disease Treatment Market Value Forecast, by Country/Sub-Region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Rare Dermatological Disease Treatment Market Attractiveness Analysis
11.6.1. By Major Indication
11.6.2. By Treatment
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-Region
12. Asia Pacific Rare Dermatological Disease Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Asia Pacific Rare Dermatological Disease Treatment Market Value Forecast, by Major Indication, 2017–2031
12.2.1. Systemic Sclerosis (Scleroderma)
12.2.2. Epidermolysis Bullosa (EB)
12.2.3. Pemphigus Vulgaris
12.2.4. Cutaneous Lupus Erythematosus
12.3. Asia Pacific Rare Dermatological Disease Treatment Market Value Forecast, by Treatment, 2017–2031
12.3.1. Corticosteroids
12.3.2. Immunosuppressants
12.3.3. Anti-inflammatory Agents
12.3.4. Antibiotics
12.3.5. Analgesics
12.3.6. Others
12.4. Asia Pacific Rare Dermatological Disease Treatment Market Value Forecast, by Distribution Channel, 2017–2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Asia Pacific Rare Dermatological Disease Treatment Market Value Forecast, by Country/Sub-Region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Rare Dermatological Disease Treatment Market Attractiveness Analysis
12.6.1. By Major Indication
12.6.2. By Treatment
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-Region
13. Latin America Rare Dermatological Disease Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Latin America Rare Dermatological Disease Treatment Market Value Forecast, by Major Indication, 2017–2031
13.2.1. Systemic Sclerosis (Scleroderma)
13.2.2. Epidermolysis Bullosa (EB)
13.2.3. Pemphigus Vulgaris
13.2.4. Cutaneous Lupus Erythematosus
13.3. Latin America Rare Dermatological Disease Treatment Market Value Forecast, by Treatment, 2017–2031
13.3.1. Corticosteroids
13.3.2. Immunosuppressants
13.3.3. Anti-inflammatory Agents
13.3.4. Antibiotics
13.3.5. Analgesics
13.3.6. Others
13.4. Latin America Rare Dermatological Disease Treatment Market Value Forecast, by Distribution Channel, 2017–2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Latin America Rare Dermatological Disease Treatment Market Value Forecast, by Country/Sub-Region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Rare Dermatological Disease Treatment Market Attractiveness Analysis
13.6.1. By Major Indication
13.6.2. By Treatment
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-Region
14. Middle East & Africa Rare Dermatological Disease Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Middle East & Africa Rare Dermatological Disease Treatment Market Value Forecast, by Major Indication, 2017–2031
14.2.1. Systemic Sclerosis (Scleroderma)
14.2.2. Epidermolysis Bullosa (EB)
14.2.3. Pemphigus Vulgaris
14.2.4. Cutaneous Lupus Erythematosus
14.3. Middle East & Africa Rare Dermatological Disease Treatment Market Value Forecast, by Treatment, 2017–2031
14.3.1. Corticosteroids
14.3.2. Immunosuppressants
14.3.3. Anti-inflammatory Agents
14.3.4. Antibiotics
14.3.5. Analgesics
14.3.6. Others
14.4. Middle East & Africa Rare Dermatological Disease Treatment Market Value Forecast, by Distribution Channel, 2017–2031
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Middle East & Africa Rare Dermatological Disease Treatment Market Value Forecast, by Country/Sub-Region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Middle East & Africa Rare Dermatological Disease Treatment Market Attractiveness Analysis
14.6.1. By Major Indication
14.6.2. By Treatment
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-Region
15. Competition Landscape
15.1. Company Profiles
15.1.1. Sanofi
15.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.1.2. Growth Strategies
15.1.1.3. SWOT Analysis
15.1.2. GlaxoSmithKline plc
15.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.2.2. Growth Strategies
15.1.2.3. SWOT Analysis
15.1.3. Novartis AG
15.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.3.2. Growth Strategies
15.1.3.3. SWOT Analysis
15.1.4. Castle Creek Biosciences, Inc.
15.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.4.2. Growth Strategies
15.1.4.3. SWOT Analysis
15.1.5. Merck & Co., Inc.
15.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.5.2. Growth Strategies
15.1.5.3. SWOT Analysis
15.1.6. Bristol-Myers Squibb Company
15.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.6.2. Growth Strategies
15.1.6.3. SWOT Analysis
15.1.7. Pfizer, Inc.
15.1.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.7.2. Growth Strategies
15.1.7.3. SWOT Analysis
15.1.8. F. Hoffmann-La Roche Ltd.
15.1.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.8.2. Growth Strategies
15.1.8.3. SWOT Analysis
15.1.9. Merck KGaA
15.1.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.9.2. Growth Strategies
15.1.9.3. SWOT Analysis
15.1.10. Eli Lilly and Company
15.1.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.10.2. Growth Strategies
15.1.10.3. SWOT Analysis
15.1.11. AbbVie, Inc.
15.1.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.11.2. Growth Strategies
15.1.11.3. SWOT Analysis
15.1.12. Krystal Biotech, Inc.
15.1.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.12.2. Growth Strategies
15.1.12.3. SWOT Analysis
15.1.13. Amryt Pharma plc
15.1.13.1. Company Overview (HQ, Business Segments, Employee Strength)
15.1.13.2. Growth Strategies
15.1.13.3. SWOT Analysis

List of Tables

Table 01: Global Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Major Indication, 2017–2031

Table 02: Global Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 03: Global Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 04: Global Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 05: North America Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 06: North America Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Major Indication, 2017–2031

Table 07: North America Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 08: North America Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 09: Europe Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 10: Europe Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Major Indication, 2017–2031

Table 11: Europe Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 12: Europe Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 13: Asia Pacific Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Asia Pacific Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Major Indication, 2017–2031

Table 15: Asia Pacific Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 16: Asia Pacific Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 17: Latin America Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 18: Latin America Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Major Indication, 2017–2031

Table 19: Latin America Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 20: Latin America Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 21: Middle East & Africa Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Middle East & Africa Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Major Indication, 2017–2031

Table 23: Middle East & Africa Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

Table 24: Middle East & Africa Rare Dermatological Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031